Clinical Research Directory

Inclusion Criteria: * • Between 21 and 75 years old. * Documented to be HBsAg positive for ≥ 6 months. * On any NA (lamivudine, adefovir, entecavir, telbivudine tenofovir) for ≥ 1 year * HBV DNA \<15 IU/ml at screening (undetectable) * Quantitative HBsAg \<100 IU/ml * Patient has agreed not to take any other investigational drug or systemic anti-viral, cytotoxic, corticosteroid, immunomodulatory agents or Chinese traditional remedies unless clinically indicated. * Patient is able to give written consent prior to study start and to comply with the study requirements. * Women of childbearing age must have a negative serum (ß-HCG) pregnancy test taken with 14 days of starting therapy Exclusion Criteria: * • Evidence of liver cirrhosis based on liver biopsy, fibroscan score \>10.5 kpa, or MRE score\>5.5kpa, or clinical evidence of cirrhosis demonstrated by presence of esophageal varices, obvious features of cirrhosis on ultrasound within the last 12 months * Evidence of decompensated liver disease or hepatocellular carcinoma. * HIV antibody or HCV antibody or HDV antibody positivity * Creatinine \> 1.5 times upper limit of normal * INR \> 1.5, uncorrected by Vitamin K therapy. * Any interferon, Immunomodulators, systemic cytotoxic agents, or systemic corticosteroids within 6 months before trial entry. * Prolonged exposure to known hepatotoxins such as alcohol or drugs. * History of clinically relevant psychiatric disease, seizures, central nervous system dysfunction, severe pre-existing cardiac, renal, hematological disease or medical illness that in the investigator's opinion might interfere with therapy. * Malignant disease within 5 years of trial entry. * Women who are pregnant and who are not practicing adequate birth control measures, or who are lactating